Abstract 6119
Background
Cancer nursing is required to identify potential advances in nursing practice, assess their relevance for ones own particular clinical situation, gather opinion on any potential change in practice (both locally and farther afield), integrate this into practice, evaluate success and then disseminate the learning from this process. Until relatively recently this process could be reasonably laborious and slow moving. However, the advent of social media sites and software and their use in nursing has streamlined this process making the gathering, group analysis and dissemination of clinical information faster and more intuitive. This study considers the authors own experience in using two social media sites (Twitter and Facebook) to gather and share clinical infomation as part of the UK Oncology Nursing Society and when setting up a new Members Interest Group for UK Lead Cancer Nurses.
Methods
This piece describes the use of Twitter and Facebook group as a professional tool to -: 1) Gather cancer nursing opinion on a particular subject (case study - Streamlining MDT Working in England and the contrubution of specialist Nursing) - potentially a ’digitall Delphi Technique’ using Twitter and Facebook 2) Build group cohesion, ask clinical questions, share information and practice and build relationships within a newly established UK group of Lead Cancer Nurses. The experiences of UKONS members of using social media professionally will be gathered, the clinical effectivenes of using social media to gather nursing opinion on a particular nursing problem (streamlining MDT working) will be analysed.
Results
The experiences of cancer nurses in using social media in professional settings will be presented as part of an overall narrative and key themes will be presented and discussed Number and range of responses to a clinical question posed on social media will be presented with consideration of how effective a tool Twitter is in gathering clinical opinion and driving improvement. Ths will be presented numerically and graphically.
Conclusions
The positive impact of the professional use of social media will be presented. Potential uses and fine tuning of these tools in cancer nursing will be considered Potential pitfalls and negative effects will also be considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract